A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

To establish the maximum tolerated dose (MTD), dose‐limiting toxicities (DLT), safety profile, and anti‐tumor efficacy of RAF265. We conducted a multicenter, open‐label, phase‐I, dose‐escalation trial of RAF265, an orally available RAF kinase/VEGFR‐2 inhibitor, in patients with advanced or metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Izar, Benjamin, Sharfman, William, Hodi, F. Stephen, Lawrence, Donald, Flaherty, Keith T., Amaravadi, Ravi, Kim, Kevin B., Puzanov, Igor, Sosman, Jeffrey, Dummer, Reinhard, Goldinger, Simone M., Lam, Lyhping, Kakar, Shefali, Tang, Zhongwen, Krieter, Oliver, McDermott, David F., Atkins, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548886/
https://www.ncbi.nlm.nih.gov/pubmed/28719152
http://dx.doi.org/10.1002/cam4.1140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548886/
https://www.ncbi.nlm.nih.gov/pubmed/28719152
http://dx.doi.org/10.1002/cam4.1140

Ejemplares similares